Elekta nabs Resonant for around $28.5M
by Brendon Nafziger, DOTmed News Associate Editor | June 02, 2010
New acquisition
Radiotherapy company Elekta bought image-guided therapy business Resonant Medical Inc. for $30 million Canadian dollars (around $28.5 million U.S. dollars) in cash, the Stockholm-based Elekta announced Monday.
Ten-year-old RMI, located in Montreal, makes 3D ultrasound equipment for guiding radiotherapy of the breast, prostate, bladder and other areas.
Elekta, which makes linear accelerators and oncology software, estimates RMI will bring it an additional $10 million Canadian dollars in revenue for 2010 and 2011, while being somewhat dilutive for earnings per share for the 2010-2011 fiscal year.
Although it hopes to one day add RMI's equipment to its linear accelerators, Elekta said RMI's products will continue to be compatible with other vendors' equipment.
In a statement, Elekta's president and CEO Tomas Puusepp said the purchase "further enhances Elekta's state-of-the-art solutions in IGRT [image-guided radiotherapy], by adding RMI's leadership in soft tissue visualization and tracking, especially focused on innovative solutions for breast and prostate cancer."
Ten-year-old RMI, located in Montreal, makes 3D ultrasound equipment for guiding radiotherapy of the breast, prostate, bladder and other areas.
Elekta, which makes linear accelerators and oncology software, estimates RMI will bring it an additional $10 million Canadian dollars in revenue for 2010 and 2011, while being somewhat dilutive for earnings per share for the 2010-2011 fiscal year.
Although it hopes to one day add RMI's equipment to its linear accelerators, Elekta said RMI's products will continue to be compatible with other vendors' equipment.
In a statement, Elekta's president and CEO Tomas Puusepp said the purchase "further enhances Elekta's state-of-the-art solutions in IGRT [image-guided radiotherapy], by adding RMI's leadership in soft tissue visualization and tracking, especially focused on innovative solutions for breast and prostate cancer."
